Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer.
macrophages
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
accepted:
26
11
2021
entrez:
31
12
2021
pubmed:
1
1
2022
medline:
23
2
2022
Statut:
ppublish
Résumé
Ovarian cancer (OvCa)-tumor-associated macrophages (TAMs) spheroids are abundantly present within ascites of high malignant patients. This study investigated the mutual interaction of OvCa cells and TAMs in the spheroids. Three-dimensional coculture system and transwell coculture system were created to mimic the OvCa and TAMs in spheroids and in disassociated state. Transwell-migration assay and scratch wound healing assay were used to measure the invasive and migratory capacity. Western blot, quantitative reverse transcription-PCR and immunostaining were used to measure the mesenchymal and epithelial markers. Flow cytometry was used to assess the polarization of TAMs. Also, the differential gene expression profile of OvCa cells and OvCa cells from spheroids were tested by RNA-sequence. Finally, the ovarian mice models were constructed by intraperitoneal injection of ID8 or OvCa-TAMs spheroids. Our results indicated that the formation of OvCa-TAMs spheroids was positive related to the malignancy of OvCa cells. M2-TAMs induced the epithelial-mesenchymal transition of OvCa cells by releasing chemokine (C-C motif) ligand 18 (CCL18) in the spheroids. While, CCL18 induced macrophage colony-stimulating factor (M-CSF) transcription in OvCa cells through zinc finger E-box-binding homeobox 1 (ZEB1). This study further indicated that M-CSF secreted by OvCa cells drived the polarization of M2-TAMs. Therefore, a CCL18-ZEB1-M-CSF interacting loop between OvCa cells and TAMs in the spheroids was identified. Moreover, with blocking the expression of ZEB1 in the OvCa cell, the formation of OvCa-TAMs spheroids was impeded. In the ovarian mice models, the formation of OvCa-TAMs spheroids in the ascites was promoted by overexpressing of ZEB1 in OvCa cells, which resulted in faster and earlier transcoelomic metastasis. These findings suggested that the formation of OvCa-TAMs spheroids resulted in aggressive phenotype of OvCa cells, as a specific feedback loop CCL18-ZEB1-M-CSF in it. Inhibition of ZEB1 reduced OvCa-TAMs spheroids in the ascites, impeding the transcoelomic metastasis and improving the outcome of ovarian patients.
Sections du résumé
BACKGROUND
Ovarian cancer (OvCa)-tumor-associated macrophages (TAMs) spheroids are abundantly present within ascites of high malignant patients. This study investigated the mutual interaction of OvCa cells and TAMs in the spheroids.
METHODS
Three-dimensional coculture system and transwell coculture system were created to mimic the OvCa and TAMs in spheroids and in disassociated state. Transwell-migration assay and scratch wound healing assay were used to measure the invasive and migratory capacity. Western blot, quantitative reverse transcription-PCR and immunostaining were used to measure the mesenchymal and epithelial markers. Flow cytometry was used to assess the polarization of TAMs. Also, the differential gene expression profile of OvCa cells and OvCa cells from spheroids were tested by RNA-sequence. Finally, the ovarian mice models were constructed by intraperitoneal injection of ID8 or OvCa-TAMs spheroids.
RESULTS
Our results indicated that the formation of OvCa-TAMs spheroids was positive related to the malignancy of OvCa cells. M2-TAMs induced the epithelial-mesenchymal transition of OvCa cells by releasing chemokine (C-C motif) ligand 18 (CCL18) in the spheroids. While, CCL18 induced macrophage colony-stimulating factor (M-CSF) transcription in OvCa cells through zinc finger E-box-binding homeobox 1 (ZEB1). This study further indicated that M-CSF secreted by OvCa cells drived the polarization of M2-TAMs. Therefore, a CCL18-ZEB1-M-CSF interacting loop between OvCa cells and TAMs in the spheroids was identified. Moreover, with blocking the expression of ZEB1 in the OvCa cell, the formation of OvCa-TAMs spheroids was impeded. In the ovarian mice models, the formation of OvCa-TAMs spheroids in the ascites was promoted by overexpressing of ZEB1 in OvCa cells, which resulted in faster and earlier transcoelomic metastasis.
CONCLUSION
These findings suggested that the formation of OvCa-TAMs spheroids resulted in aggressive phenotype of OvCa cells, as a specific feedback loop CCL18-ZEB1-M-CSF in it. Inhibition of ZEB1 reduced OvCa-TAMs spheroids in the ascites, impeding the transcoelomic metastasis and improving the outcome of ovarian patients.
Identifiants
pubmed: 34969774
pii: jitc-2021-003973
doi: 10.1136/jitc-2021-003973
pmc: PMC8718465
pii:
doi:
Substances chimiques
CCL18 protein, human
0
Chemokines, CC
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Mol Sci. 2020 Oct 26;21(21):
pubmed: 33114763
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
Nature. 2015 Nov 26;527(7579):525-530
pubmed: 26560028
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Cell Death Dis. 2020 Apr 16;11(4):234
pubmed: 32300100
Cancer Lett. 2008 Dec 18;272(2):177-85
pubmed: 18579285
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Cell Stem Cell. 2015 Jan 8;16(1):67-79
pubmed: 25575080
Oncotarget. 2015 Jun 20;6(17):15578-93
pubmed: 26008969
BMC Cancer. 2012 Jan 24;12:35
pubmed: 22273460
Int J Exp Pathol. 2020 Dec;101(6):203-214
pubmed: 32985776
Cancer Res. 2017 Apr 15;77(8):1955-1967
pubmed: 28209618
Theranostics. 2020 Jul 9;10(18):8365-8381
pubmed: 32724475
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
Cancer Biol Ther. 2019;20(7):956-966
pubmed: 31062668
Cancer Sci. 2018 May;109(5):1309-1318
pubmed: 29527764
J Immunother Cancer. 2019 Jul 19;7(1):190
pubmed: 31324218
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Exp Cell Res. 2020 Sep 1;394(1):112167
pubmed: 32649943
Lancet Oncol. 2006 Nov;7(11):925-34
pubmed: 17081918
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Cell Rep. 2015 Jan 13;10(2):131-9
pubmed: 25578726
Gynecol Oncol. 2004 Apr;93(1):170-81
pubmed: 15047232
Int J Cancer. 2021 Jul 1;149(1):21-30
pubmed: 33231290
Oncotarget. 2015 Oct 27;6(33):34758-73
pubmed: 26416449
PLoS One. 2014 Jan 07;9(1):e84941
pubmed: 24409314
J Clin Invest. 2012 May;122(5):1849-68
pubmed: 22505459
Cancer Cell. 2013 Feb 11;23(2):249-62
pubmed: 23410977
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
EMBO J. 2017 Nov 15;36(22):3336-3355
pubmed: 29038174
Nat Rev Cancer. 2019 Dec;19(12):716-732
pubmed: 31666716
Cancer Res. 2021 Mar 15;81(6):1595-1606
pubmed: 33239429
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Mol Cell Biochem. 2021 Apr;476(4):1643-1650
pubmed: 33417164
Cell Death Dis. 2013 Nov 07;4:e915
pubmed: 24201814
Am J Physiol Cell Physiol. 2015 Oct 1;309(7):C444-56
pubmed: 26224579
Cancer Sci. 2016 Sep;107(9):1173-8
pubmed: 27297561
Cell Death Differ. 2014 Feb;21(2):247-57
pubmed: 24013721
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Nat Commun. 2020 Dec 8;11(1):6298
pubmed: 33293516
J Cell Sci. 2013 May 15;126(Pt 10):2256-66
pubmed: 23525011
Cell. 2012 Jan 20;148(1-2):349-61
pubmed: 22265420
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2337-E2346
pubmed: 28270621
Cancer Sci. 2017 Mar;108(3):283-289
pubmed: 28064442
Cell Stem Cell. 2012 Jun 14;10(6):717-728
pubmed: 22704512
Cells. 2020 May 22;9(5):
pubmed: 32456078
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Nat Rev Cancer. 2021 May;21(5):325-338
pubmed: 33547455